Radiance Biopharma acquired global rights outside certain Asian markets for a bispecific nanobody antibody-drug conjugate targeting c-MET and EGFR to treat solid tumors, in a deal potentially worth $1.165 billion. The drug candidate, RB-601, is in Phase I trials in China and has FDA clearance for U.S. studies. Novatim Immune Therapeutics, based in China, retains rights in select Asian regions. The upfront payment was $15 million with additional regulatory and commercial milestones plus tiered royalties.